bims-myxlip Biomed News
on Myxoid liposarcoma
Issue of 2024‒10‒06
one paper selected by
Laura Mannarino, Humanitas Research



  1. Cancers (Basel). 2024 Sep 23. pii: 3233. [Epub ahead of print]16(18):
      BACKGROUND: Myxoid liposarcoma predominantly affects young and middle-aged individuals, and little is known regarding treatment tolerability and outcomes in older patients. This study aims to better understand this older patient population.METHODS: This single institution retrospective study included patients aged 70 years and older with localized (non-metastatic) myxoid liposarcoma.
    RESULTS: Sixteen patients were included. The median age was 75 years, and 9 (56%) were female. Fourteen (88%) were extremity tumors and two (12%) were trunk. The median tumor size was 10.4 cm (range, 3.6 to 28 cm). Five (31%) tumors had a round cell component. All patients had surgery. Fourteen (88%) had perioperative radiation, and three (19%) had perioperative chemotherapy. One patient had postoperative infection, and one patient had neutropenic fever from preoperative chemotherapy. The median follow up from surgery was 6.3 years. Eight (50%) patients died from MLPS. The median relapse-free survival and overall survival were 34 months and 75 months, respectively.
    CONCLUSIONS: Most older patients with localized MLPS received perioperative radiation therapy with surgery, and few serious toxicities were reported. Even with treatment, half of the patients relapsed.
    Keywords:  myxoid liposarcoma; older patients; soft tissue sarcoma
    DOI:  https://doi.org/10.3390/cancers16183233